Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
Year: 2018
Type: article
Study design: Clinical Trial
Source: The Lancet Haematology
Authors: Jennifer R Brown, Mehdi Hamadani, John Hayslip, Ann Janssens, Nina Wagner-Johnston, Oliver Ottmann, Jon Arnason, Hervé Tilly, Michael Millenson, Fritz Offner, Nashat Y Gabrail, Siddhartha Ganguly, Sikander Ailawadhi, Siddha Kasar, Arnon P Kater, Jeanette K Doorduijn, Lei Gao, Joanne J Lager, Bin Wu, Coumaran Egile, Marie José Kersten
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, West Virginia University, Medical College of Wisconsin, University of Kentucky, Markey Cancer Center, Universitair Ziekenhuis Leuven, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Cardiff University, Beth Israel Deaconess Medical Center, Inserm, Centre Henri Becquerel, Université de Rouen Normandie, Fox Chase Cancer Center, Ghent University Hospital, Gabrail Cancer Center, University of Kansas Medical Center, Mayo Clinic in Florida, Amsterdam UMC Location University of Amsterdam, Erasmus MC Cancer Institute, Sanofi (France)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W2792557374